Difference in the running biomechanics between preschoolers and adults

Background: High vertical loading rate is associated with a variety of running-related musculoskeletal injuries. There is evidence supporting that non-rearfoot footstrike pattern, greater cadence, and shorter stride length may reduce the vertical loading rate. These features appear to be common among preschoolers, who seem to experience lower running injury incidence, leading to a debate whether adults should accordingly modify their running form. Objective: This study sought to compare the running biomechanics between preschoolers and adults. Methods: Ten preschoolers (4.2 ± 1.6 years) and ten adults (35.1 ± 9.5 years) were recruited Q3 and ran overground with their usual shoes at a self-selected speed. Vertical average (VALR) and vertical instantaneous loading rate (VILR) were calculated based on the kinetic data. Footstrike pattern and spatiotemporal parameters were collected using a motion capture system. Results: There was no difference in normalized VALR (p = 0.48), VILR (p = 0.48), running speed (p = 0.85), and footstrike pattern (p = 0.29) between the two groups. Preschoolers demonstrated greater cadence (p < 0.001) and shorter normalized stride length (p = 0.01). Conclusion: By comparing the kinetic and kinematic parameters between children and adults, our findings do not support the notion that adults should modify their running biomechanics according to the running characteristics in preschoolers for a lower injury risk. © 2020 Associac¸ao˜ Brasileira de Pesquisa e Pos-Graduac¸ ´ ao˜ em Fisioterapia. Published by Elsevier Editora Ltda. All rights reserved

Ultrastrong conductive in situ composite composed of nanodiamond incoherently embedded in disordered multilayer graphene

Traditional ceramics or metals cannot simultaneously achieve ultrahigh strength and high electrical conductivity. The elemental carbon can form a variety of allotropes with entirely different physical properties, providing versatility for tuning mechanical and electrical properties in a wide range. Here, by precisely controlling the extent of transformation of amorphous carbon into diamond within a narrow temperature–pressure range, we synthesize an in situ composite consisting of ultrafine nanodiamond homogeneously dispersed in disordered multilayer graphene with incoherent interfaces, which demonstrates a Knoop hardness of up to ~53 GPa, a compressive strength of up to ~54 GPa and an electrical conductivity of 670–1,240 S m(–1) at room temperature. With atomically resolving interface structures and molecular dynamics simulations, we reveal that amorphous carbon transforms into diamond through a nucleation process via a local rearrangement of carbon atoms and diffusion-driven growth, different from the transformation of graphite into diamond. The complex bonding between the diamond-like and graphite-like components greatly improves the mechanical properties of the composite. This superhard, ultrastrong, conductive elemental carbon composite has comprehensive properties that are superior to those of the known conductive ceramics and C/C composites. The intermediate hybridization state at the interfaces also provides insights into the amorphous-to-crystalline phase transition of carbon

Pharmacokinetic study of isoquercitrin in rat plasma after intravenous administration at three different doses

The aim of this study is to develop a simple and specific HPLC method using vitexin as the internal standard to investigate the pharmacokinetics of isoquercitrin (ISOQ) after three different doses administrated intravenously to rats. The pharmacokinetic parameters were calculated by both compartmental and non-compartmental approaches. The results showed that ISOQ fitted a three-compartment open model. The values of AUC increased proportionally within the range of 5-10 mg·kg-1. Moreover, a half-life, b half-life, ªCL, MRT0-t and MRT0→∞ of ISOQ in rats showed significant differences between 20 mg·kg-1 and other doses, indicating that ISOQ presented dose-dependent pharmacokinetics in the range of 5-10 mg·kg-1 and non-linear pharmacokinetics at higher doses

A Measurement of Psi(2S) Resonance Parameters

Cross sections for e+e- to hadons, pi+pi- J/Psi, and mu+mu- have been measured in the vicinity of the Psi(2S) resonance using the BESII detector operated at the BEPC. The Psi(2S) total width; partial widths to hadrons, pi+pi- J/Psi, muons; and corresponding branching fractions have been determined to be Gamma(total)= (264+-27) keV; Gamma(hadron)= (258+-26) keV, Gamma(mu)= (2.44+-0.21) keV, and Gamma(pi+pi- J/Psi)= (85+-8.7) keV; and Br(hadron)= (97.79+-0.15)%, Br(pi+pi- J/Psi)= (32+-1.4)%, Br(mu)= (0.93+-0.08)%, respectively.Comment: 8 pages, 6 figure

Measurements of the Mass and Full-Width of the ηc\eta_c Meson

In a sample of 58 million $J/\psi$ events collected with the BES II detector, the process J/$\psi\to\gamma\eta_c$ is observed in five different decay channels: $\gamma K^+K^-\pi^+\pi^-$, $\gamma\pi^+\pi^-\pi^+\pi^-$, $\gamma K^\pm K^0_S \pi^\mp$ (with $K^0_S\to\pi^+\pi^-$), $\gamma \phi\phi$ (with $\phi\to K^+K^-$) and $\gamma p\bar{p}$. From a combined fit of all five channels, we determine the mass and full-width of $\eta_c$ to be $m_{\eta_c}=2977.5\pm1.0 ({stat.})\pm1.2 ({syst.})$ MeV/$c^2$ and $\Gamma_{\eta_c} = 17.0\pm3.7 ({stat.})\pm7.4 ({syst.})$ MeV/$c^2$.Comment: 9 pages, 2 figures and 4 table. Submitted to Phys. Lett.

Measurement of Branching Ratios for ηc\eta_c Hadronic Decays

In a sample of 58 million $J/\psi$ events collected with the BES II detector, the process J/$\psi\to\gamma\eta_c$ is observed in five decay channels: $\eta_c \to K^+K^-\pi^+\pi^-$, $\pi^+\pi^-\pi^+\pi^-$, $K^\pm K^0_S \pi^\mp$ (with $K^0_S\to\pi^+\pi^-$), $\phi\phi$ (with $\phi\to K^+K^-$) and $p\bar{p}$. From these signals, we determine $Br(J/\psi\to\gamma\eta_c)\times Br(\eta_c\to K^+K^-\pi^+\pi^-)$ $=(1.5\pm0.2\pm0.2)\times10^{-4}$, $Br(J/\psi\to\gamma\eta_c)\times Br(\eta_c\to \pi^+\pi^-\pi^+\pi^-)$ $=(1.3\pm0.2\pm0.4)\times10^{-4}$, $Br(J/\psi\to\gamma\eta_c)\times Br(\eta_c\to K^\pm K_{S}^{0}\pi^\mp)$ $=(2.2\pm0.3\pm0.5)\times10^{-4}$, $Br(J/\psi\to\gamma\eta_c)\times Br(\eta_c\to \phi\phi)$ $=(3.3\pm0.6\pm0.6)\times10^{-5}$ and $Br(J/\psi\to\gamma\eta_c)\times Br(\eta_c\to p\bar{p})$ $=(1.9\pm0.3\pm0.3)\times10^{-5}$.Comment: 8 pages, 1 figures and 4 table. Submitted to Phys. Lett.

Evidence of psi(3770) non-DD-bar Decay to J/psi pi+pi-

Evidence of $\psi(3770)$ decays to a non-${D \bar D}$ final state is observed. A total of $11.8 \pm 4.8 \pm 1.3$ \psi(3770) \to \PPJP events are obtained from a data sample of 27.7 $\rm {pb^{-1}}$ taken at center-of-mass energies around 3.773 GeV using the BES-II detector at the BEPC. The branching fraction is determined to be BF(\psi(3770) \to \PPJP)=(0.34\pm 0.14 \pm 0.09)%, corresponding to the partial width of \Gamma(\psi(3770) \to \PPJP) = (80 \pm 33 \pm 23) keV.Comment: 8 pages, 7 figures, Submitted to Physics Letters

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362